Hepatocellular hypertrophy is typically identified by light microscopy and is associated with increased protein synthesis (assessed biochemically) and increased cytoplasmic organelles such as endoplasmic reticulum and peroxisomes (assessed by electron microscopy), or accumulation of intracellular components such as glycogen, lipid, or water
A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Peptides are research chemicals and are not approved for human consumption
A recent study of moderately overweight women found that L-carnitine did not significantly alter body weight, body fat, or lean body mass
Gene expression modulation
GLP1 injections are given subcutaneously (under the skin) in one of three areas: the abdomen (at least 5cm from the belly button), the front of the thigh (upper leg), or the back of the upper arm (if administered by another person)